Amyloidosis as a clinical problem (a difficult case of establishing a diagnosis of renal amyloidosis)

Authors

DOI:

https://doi.org/10.22141/2307-1257.9.3.2020.211462

Keywords:

amyloidosis, clinical case, kidneys

Abstract

Amyloidosis is one of the most complex diseases in therapeutic practice and can lead to irreversible kidney damage with the development of chronic renal failure. Therefore, the issue of timely diagnosis and early treatment of this disease is very relevant. The article presents a clinical case of renal amyloidosis.

Downloads

Download data is not yet available.

References

Rodionova VV, Boyko OO, Turenko OA, Denisenko OO. Predictors of chronic heart failure development and progression in pre-dialysis patients with chronic kidney disease. Počki. 2019;8(1):29-33. doi:10.22141/2307-1257.8.1.2019.157793. (in Ukrainian).

Rameev VV, Kozlovskaia LV. Amyloidosis: modern methods of diagnosis and treatment. Available from: https://umedp.ru/articles/amiloidoz_sovremennye_metody_diagnostiki_i_lecheniya.html. (in Russian).

Leung N, Kyle RA, Appel GB, authors; Glassock RJ, Lam AQ, editors. Renal amyloidosis. Available from: https://www.uptodate.com/contents/renal-amyloidosis. Accessed: August 19, 2019.

Varshavskii VA, Proskurneva EP. Importance and methods of morphological diagnosis of amyloidosis in modern medicine. Prakticheskaia nefrologiia. 1998;(2):16-23. (in Russian).

Sangle N. Renal amyloidosis. Available from: https://www.pathologyoutlines.com/topic/kidneyamyloidosis.html. Accessed June 24, 2020.

Westermark P, Benson MD, Buxbaum JN, et al. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid. 2005;12(1):1-4. doi:10.1080/13506120500032196.

Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015;168(2):186-206. doi:10.1111/bjh.13155.

Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood. 2007;110(2):787-788. doi:10.1182/blood-2007-02-076034.

Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107(19):2446-2452. doi:10.1161/01.CIR.0000068313.67758.4F.

Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55(3):499-504. doi:10.1373/clinchem.2008.117143.

Gertz MA. The classification and typing of amyloid deposits. Am J Clin Pathol. 2004;121(6):787-789. doi:10.1309/TR4L-GLVR-JKAM-V5QT.

Zakharova EV, Khrykina AV, Proskurneva EP, Varshavsky VA. A case of primary amyloidosis: difficulties of diagnostics and treatment. Nephrology and Dialysis. 2002;4(1):54-61. (in Russian).

Fuah KW, Lim CTS Renal-limited AL amyloidosis - a diagnostic and management dilemma. BMC Nephrol. 2018;19(1):307. doi:10.1186/s12882-018-1118-8.

Smirnova AG, Bondarenko SN, Kisina AA, et al. Current therapies for AL amyloidosis: literature review and our data. Klinicheskaia onkogematologiia. 2013;6(3):303-311. (in Russian).

Gertz MA, Reece D, Zonder J. Amyloidosis. Available from: https://bestpractice.bmj.com/topics/en-gb/444/. Accessed: October 2018.

Lysenko LV, Rameev VV; Scientific Society of Nephrologists of Russia; Association of Nephrologists of Russia. Natsional'nye klinicheskie rekomendatsii “Diagnostika i lechenie AA-i AL-amiloidoza” [National clinical guidelines for the diagnosis and treatment of AA-and AL amyloidosis]. Moscow; 2016. (in Russian).

Weidemann F, Strotmann JM. Use of tissue Doppler imaging to identify and manage systemic diseases. Clin Res Cardiol. 2008;97(2):65-73. doi:10.1007/s00392-007-0566-0.

Mahmood S, Venner CP, Sachchithanantham S, et al. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. Br J Haematol. 2014;166(6):842-848. doi:10.1111/bjh.12973.

Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010;116(23):4777-4782. doi:10.1182/blood-2010-07-294405.

Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95(7):848-860. doi:10.1002/ajh.25819.

Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010;116(23):4777-4782. doi:10.1182/blood-2010-07-294405.

Petrovskii BV, editor. Bol'shaia meditsinskaia entsiklopediia. Tom 1: Antibioz [Big Medical Encyclopedia. Vol 1: Antibiosis]. Moscow: Sovetskaia entsiklopediia; 1974. 576 p. (in Russian).

Downloads

Published

2021-09-08

How to Cite

Rodionova, V., Turenko, O., Kuzhevsky, I., Tsyhankov, K., Denisenko, O., Razinina, Y., & Boiko, O. (2021). Amyloidosis as a clinical problem (a difficult case of establishing a diagnosis of renal amyloidosis). KIDNEYS, 9(3), 159–168. https://doi.org/10.22141/2307-1257.9.3.2020.211462

Issue

Vol. 9 No. 3 (2020)

Section

Clinical Observation

License

Copyright (c) 2020 V.V. Rodionova, O.A. Turenko, I.V. Kuzhevsky, K.V. Tsyhankov, O.O. Denisenko, Yu.O. Razinina, O.O. Boiko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.